ATAGI met on 28 April 2021 to review the latest developments relating to the AstraZeneca COVID-19 vaccine and Thrombosis and Thrombocytopenia Syndrome (TTS) cases in Australia and overseas.
ATAGI considered additional information from the Therapeutic Goods Administration (TGA) including risk estimates from the European Medicines Agency and current confirmed cases and those under investigation in Australia. The latest TGA statement on TTS cases can be found here.
In addition, ATAGI also considered international case definitions for TTS from the UK and Brighton Collaboration in the US. Case definitions outline processes required in order to identify and confirm TTS cases, including imaging study, surgical or pathology findings.
The last three cases of TTS in Australia was confirmed based on a draft UK case definition.
At this time, there is no update to the ATAGI statement from 23 April 2021 in relation to the use of the AstraZeneca vaccine.
The following ATAGI / Department of Health documents have been updated or are in development:
- Provider and patient information sheets on TTS
- Consent form, Provider guide and FAQs, Information sheet on AstraZeneca and After your AstraZeneca vaccine
- Shared decision making guides
- Risk-benefit from AstraZeneca vaccine
- Clinical Guidance